Comparative Pharmacology
Head-to-head clinical analysis: LIBERVANT versus VALIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIBERVANT versus VALIUM.
LIBERVANT vs VALIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABA-A receptor positive allosteric modulator; enhances inhibitory neurotransmission.
Benzodiazepine that enhances the effect of GABA at GABA-A receptors, increasing chloride ion conductance and producing neuronal hyperpolarization.
0.25 mg intravenously over 2 minutes, may repeat once after 15 minutes if inadequate response; maximum total dose 0.5 mg.
Oral: 2-10 mg 2-4 times daily. IV/IM: 5-10 mg, repeat in 3-4 hours if needed; max 30 mg in 8 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 2–4 hours in patients with normal renal function; may be prolonged up to 8–12 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life of diazepam: 20–50 hours; active metabolite desmethyldiazepam half-life: 36–200 hours (accumulates with chronic dosing, prolonging clinical effects).
Primarily renal excretion of unchanged drug (approximately 85%) and glucuronide conjugates (approximately 10%); biliary/fecal excretion accounts for less than 5%.
Renal: <1% unchanged; hepatic metabolism to active metabolites (desmethyldiazepam, temazepam, oxazepam); metabolites excreted renally as glucuronides. Fecal: minor.
Category C
Category C
Benzodiazepine
Benzodiazepine